“In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing portfolio of three promising Phase 3 assets on track for topline data in 2026 is well-supported by our science and our progress on execution,” said Victor Perlroth, M.D., Chairman and Chief Executive Officer of Kodiak Sciences (KOD). Kodiak ended the first quarter of 2025 with $138.9M of cash and cash equivalents. “We believe that our current cash will support our current and planned operations into 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences: Hold Rating Amidst Strategic Advances and Long-term Catalysts
- Promising Outlook for Kodiak Sciences: Buy Rating Backed by Upcoming R&D Day and Strategic Advancements
- Kodiak Sciences Advances Retinal Therapies with Promising Pipeline
- Kodiak Sciences reports Q4 EPS 84c, consensus (86c)
- KOD Upcoming Earnings Report: What to Expect?